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West Nile virus (WNV) NS4B is a small hydrophobic nonstructural protein that is hypothesized to participate both in viral replication and
evasion of host innate immune defenses. The protein has four cysteine residues (residues 102, 120, 227, and 237). Since cysteines are often critical
for the function of proteins, each of the four cysteine residues found in WNV NS4B was mutated to serine by site-directed mutagenesis. While
three of these substitutions had little effect on replication or mouse virulence phenotypes, the C102S mutation was associated with a temperature-
sensitive phenotype at 41 °C as well as attenuation of the neuroinvasive and neurovirulence phenotypes in mice.
© 2006 Elsevier Inc. All rights reserved.Keywords: West Nile virus; Flavivirus; NS4B protein; Attenuated phenotype; CysteineIntroduction
West Nile virus (WNV) is a mosquito-transmitted
member of the genus Flavivirus, family Flaviviridae. The
WNV genome is a single-stranded, positive-sense RNA
molecule approximately 11 kb in length encoding a single
polyprotein that is co- and post-translationally cleaved by a
combination of viral and host proteases to produce three
structural (C, prM, and E) and seven nonstructural (NS)
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).
While the structural proteins, NS5 polymerase, and NS3
protease have been relatively well characterized, the
structure and function of the four small hydrophobic⁎ Corresponding author. Department of Pathology, University of Texas
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doi:10.1016/j.virol.2006.03.007proteins NS2A, NS2B, NS4A, and NS4B remain poorly
defined. NS4B is approximately 27 kDa in size and is
cleaved from the translated polyprotein by a combination of
viral and host proteases (Chambers et al., 1989; Preugschat
and Strauss, 1991). NS4B is believed to associate with other
components of the viral replication complex in addition to
contributing to evasion of host immune defenses (Lundin et
al., 2003; Munoz-Jordan et al., 2005). Within the family
Flaviviridae, WNV NS4B exhibits ∼35% identity with other
mosquito-borne flaviviruses such as yellow fever virus
(YFV) and members of the dengue (DEN) serogroup.
Although hepatitis C virus (HCV) NS4B displays negligible
amino acid similarity with the WNV NS4B protein, a
common function is suggested by similarities in the
predicted topologies of these two proteins. Lundin et al.
(2003) expressed recombinant HCV NS4B-GFP fusion
protein in Hep3B cells and found that it was primarily
localized to the endoplasmic reticulum and distributed in a
246 Rapid Communicationreticular web-like pattern with scattered dense spots thought
to represent foci of replication. Accumulation of Kunjin
virus NS4B in the perinuclear region along with induction
of membrane proliferation has been described, and there is
evidence that NS4B can translocate into the nucleus
(Westaway et al., 1997). Recently, DEN2 virus NS4B was
found to inhibit the interferon-signaling cascade at the levelof nuclear STAT phosphorylation (Munoz-Jordan et al.,
2004).
A number of publications have described mutations in the
NS4B protein in attenuated or passage-adapted mosquito-
borne flaviviruses suggesting this protein plays a vital role
in replication and pathogenesis. A single coding mutation
(P101L) in DEN4 virus NS4B conferred a small-plaque
Fig. 1. Primary amino acid sequence of NS4B of different flaviviruses and predicted secondary structure of WNV NS4B. (A) Complete NS4B amino acid alignments
including both tick-borne and mosquito-borne flaviviruses show conservation of the WNV C102 residue within the DEN and JE genetic groups. Virus abbreviations:
LGT: Langat; TBE: Tick-borne encephalitis; OHF: Omsk hemorrhagic fever; POW: Powassan; YFasibi: Yellow fever Asibi strain; YF17D: Yellow fever 17D vaccine
strain; DEN1: Dengue 1; DEN2: Dengue 2; DEN3: Dengue 3; DEN4: Dengue 4; JE: Japanese encephalitis; MVE: Murray Valley encephalitis; KUN: Kunjin; WN:
West Nile NY99 strain; SLE: St. Louis encephalitis; USU: Usutu. (B) A model for the NS4B protein was produced based on hydrophobicity plots. C102 is predicted to
reside at the junction of an ectodomain and a transmembrane domain. C120 is predicted to localize to a membrane-spanning region while both C227 and C237 are
thought to reside in the C-terminal tail.
247Rapid Communicationphenotype in C6/36 cells while at the same time increasing
plaque size in Vero cells two-fold and Huh7 cells three-fold
(Hanley et al., 2003). Pletnev et al. (2002) described DEN4
NS4B T105I and L112S substitutions that occurred in a
chimeric virus expressing WNV structural proteins in a
DEN4 virus backbone. Blaney et al. (2003) noted a NS4B
L112F mutation in a DEN4 virus passaged in Vero cells.
The live attenuated Japanese encephalitis virus (JEV)
vaccine strain SA14-14-2 has an I106V substitution in
NS4B (Ni et al., 1995). A viscerotropic Asibi strain of YFV
generated by passaging seven times through hamsters
accumulated seven amino acid substitutions in the translated
polyprotein including a V98I substitution in NS4B
(McArthur et al., 2003). Interestingly, YFV vaccine strains
also display a mutation in NS4B at I95M (Hahn et al.,
1987; Wang et al., 1995). When the NS4B proteins from
different flaviviruses are aligned, it becomes clear that these
mutations are all located in a similar region of the protein
(Fig. 1A). Since the NS4B protein appears to be important
for the phenotype of flaviviruses, we have examined the
effects of mutating the four cysteine residues in the NS4B
protein of WNV, as cysteine residues are often critical for
the proper function of a protein. We have determined that
residue NS4B C102 plays an important role in the growth
and mouse virulence phenotypes of WNV.
Results
Rescue of recombinant viruses
Secondary structure predictions of the flavivirus NS4B
protein utilizing the SOSUI program (Hirokawa et al., 2003)
suggest that it is a very hydrophobic protein with four putative
transmembrane regions (see Fig. 1B). The WNV NS4B protein
contains four cysteine residues at positions 102, 120, 227, and237. Examination of amino acid alignments of flaviviral NS4B
proteins revealed that C102 and C120 localize to a central region
where mutations are frequently observed in attenuated or
passage-adapted strains of JE, YF, and DEN4 viruses (see
Introduction). While C102 is conserved throughout all members
of the DEN and JE serogroups, C120 is unique to WN and
Kunjin viruses. Both C227 and C237 are located in the C-
terminal region of the protein. The C227 residue is conserved
within the JE serogroup, while C237 is again unique to WN and
Kunjin viruses. Since cysteines are often critical for proper
protein function, the role of the four cysteine residues in the
NS4B protein was investigated by mutating each of them to a
serine using reverse genetics. Utilizing the two-plasmid
infectious clone of WNV NY99 (Beasley et al., 2005), mutant
viruses encoding a C102S, C120S, C227S, or C237S substitu-
tion in the NS4B protein were rescued. Sequencing of the NS4B
region of recombinant viruses was conducted to confirm the
presence of the mutation of interest. The complete genome of the
C102S virus was sequenced, and no additional mutations were
detected. The original virus yield from the transfection was used
in all subsequent studies with no further passaging. All
recombinant viruses generated infectivity titers in excess of
5 log10 pfu/ml by 5–6 days post-transfection.
Temperature sensitivity assay
Each recombinant mutant virus was investigated for
temperature sensitivity by plaquing in Vero cells at both 37 °C
and 41 °C. Wild-type virus and the C120S, C227S, and C237S
mutant viruses all showed comparable levels of plaquing
efficiency at both temperatures (Table 1). In contrast, the C102S
mutant exhibited an infectivity titer of 5.7 log10 pfu/ml at 37 °C,
but no plaques (≤0.7 log10 pfu/ml) were detectable at 41 °C,
exhibiting a reduction in efficiency of plaquing of >5.0 log10
pfu/ml. However, the C102S mutant was not temperature
Table 1
Mouse virulence and temperature sensitive phenotypes of recombinant wild-type WNV and the five cysteine mutants
Virus a Mouse virulence b Temperature sensitivity c
i.p. LD50
(pfu)
i.p. AST
(days ± SD)
i.p. PD50
(pfu)
i.c. LD50
(pfu)
i.c. PD50
(pfu)
Viral Titer/ml
at 37 °C (log10 pfu)
Viral Titer/ml
at 41 °C (log10 pfu)
Relative change in viral titer
[log10 (pfu41 °C/pfu37 °C)]
NY99 0.5 7.4 ± 0.9 n.d. d 0.2 n.d. 6.5 6.7 0.2
C102S >10,000 >35 0.4 >1000 1.2 5.9 <0.7 >−5.2
C120S 0.7 8.0 ± 1.0 n.d. n.d. n.d. 5.4 5.2 −0.2
C227S 2 9.4 ± 2.4 n.d. n.d. n.d. 5.9 5.5 −0.4
C237S 5 8.6 ± 1.1 n.d. n.d. n.d. 5.2 5.3 0.1
C102A 0.7 7.8 ± 1.4 n.d. n.d. n.d. 6.2 4.3 −1.9
a Infectious clone-derived wild-type WNV, strain NY99, and five cysteine-to-serine mutants in NS4B were tested. C102S = cysteine-to-serine mutation at amino
acid residue NS4B-102.
b Median lethal viral dose (LD50) or median protective viral dose (PD50) following intraperitoneal (i.p.) or intracerebral (i.c.) administration of virus. AST = average
survival time.
c Virus seeds were plaque titrated in Vero cells under agar overlay at 37 °C and 41 °C. The relative change [log10 (titer at 41 °C/titer at 37 °C)] in viral titer at the
higher temperature indicates the degree of temperature sensitivity.
d n.d. = not done.
248 Rapid Communicationsensitive at 39.5 °C and plaqued as well at this temperature as it
did at 37 °C (data not shown).
Multiplication kinetics in cell culture
Growth curves of wild-type WNV NY99 and the four
cysteine mutants were undertaken at a MOI of 0.01 in Vero cells
at both 37 °C and 41 °C (Figs. 2A and B). Other than the C102S
mutant, the cysteine mutants grew as well as wild-type virus at
both 37 °C and 41 °C. Although the C102S mutant grew
comparably to wild-type virus at 37 °C (Fig. 2A), its peak
infectivity titers were approximately 5 log10 lower than wild-Fig. 2. Multiplication kinetics of recombinant wild-type and cysteine mutant viruses i
Growth curves were conducted at a MOI of 0.01, and the limit of detection was≤0.7
at 37 °C, (D) C6/36 cells at 28 °C.type WNV at 41 °C (Fig. 2B). Growth curves were also
conducted in mouse neuroblastoma Neuro2A cells (Fig. 2C)
and mosquito C6/36 cells (Fig. 2D) grown at 37 °C or 28 °C,
respectively. Recombinant viruses encoding C102S, C120S,
C227S, and C237S substitutions multiplied at levels compara-
ble to wild type in both cell lines at those temperatures.
C102S mutant is attenuated for neuroinvasiveness and
neurovirulence in mice
We have previously described a mouse model to investigate
neuroinvasiveness and neurovirulence of WNV via intraperitonealn monkey kidney Vero (A), mouse Neuro2A (C), and mosquito C6/36 (D) cells.
log10 PFU/ml. (A) Vero cells at 37 °C, (B) Vero cells at 41 °C, (C) Neuro2A cells
249Rapid Communication(i.p.) or intracerebral (i.c.) inoculation of three-week-oldNIH Swiss
mice, respectively (Beasley et al., 2002). The C120S, C227S, and
C237S mutants were as virulent as wild-type WNV following i.p.
inoculation in terms of lethality and average survival time (Table 1).
In contrast, the C102S mutant was attenuated when inoculated by
the i.p. route with no mice showing clinical signs of infection
following inoculation with virus doses as high as 10,000 pfu. The
C102S mutant was also found to be attenuated for neurovirulence.
The C102S mutant failed to kill any mice at an inoculum of 1000
pfu, whereas wild-type recombinant WNV had a LD50 value of 0.2
pfu indicating at least 5000-fold attenuation. While the C102S
mutant was highly attenuated, it remained capable of inducing a
protective immune response with an i.p. median protective dose
(PD50) value of 0.4pfu.
Multiplication of the C102S mutant in mice
Mice were inoculated with 100 pfu of either wild-type or
C102SmutantWNV via the intraperitoneal route, and serum and
brain infectivity titers were determined each day post-infection
(Table 2). The peak viremia of wild-typeWNVoccurred on day 2
post-infection and reached 5.4 log10 pfu/ml, while the peak
viremia for the C102S mutant reached 3.4 log10 pfu/ml and also
occurred on day 2. Peak brain titers reached 7.4 log10 pfu/brain
for the wild-type virus on day 6 post-infection, while the virus
was never detected in the brains of C102S virus-infected mice.
The limit of detection was 1.7 log10 pfu/ml for serum and
2.7 log10 pfu/brain for the brain. RT-PCR amplification of RNA
isolated from the brains of virus-infected mice at days 4 through
6 post-infection, revealed that no PCR product was detected
from C102S virus-infected mouse brain, while virus wasTable 2
Viremia and brain titers from mice inoculated with 100pfu of either wild-type
WNVor C102S mutant virus via the intraperitoneal route
Day Mouse
number
NY99 C102S
NY99 i.p. Serum
(log10 PFU/ml)
Brain Titer
(log10 PFU/
brain)
C102S i.p.
Serum (log10
PFU/ml)
Brain Titer
(log10 PFU/
brain)
1 1 3.0 – a 2.5 –
2 4.4 – 2.0 –
3 4.8 1.9 –
2 1 4.4 – 2.5 –
2 5.2 – 3.0 –
3 5.4 3.4 –
3 1 2.7 – 1.7 –
2 2.2 – 2.8 –
3 2.6 3.3 –
4 1 – 4.6 – –
2 2.2 4.0 1.7 –
3 2.1 4.3 – –
5 1 – 4.9 – –
2 – 6.0 – –
3 – 4.5 – –
6 1 – 6.3 – –
2 – 6.8 – –
3 – 7.4 – –
a No virus detected. The limits of detection were 1.7 log10 pfu/ml in the serum
and 2.7 log10 pfu/brain.demonstrated in the brains of wild-type infected mice (data not
shown). Thus, the attenuated C102S mutant exhibited signifi-
cant viremia, but there was no evidence that the virus entered the
brain.
Reversion of the C102S mutation
To generate temperature-sensitive revertants, growth curve
samples harvested at the 48-h time point from either 37 °C or
41 °C were tested for the presence of revertants by picking
plaques at 41 °C, amplifying in Vero cells at 37 °C, and
determining the efficiency of plaquing at 37 °C versus 41 °C.
Plaque picks were identified that contained a S102C reversion,
lacked temperature sensitivity at 41 °C, and displayed
neuroinvasiveness and neurovirulence characteristics similar
to those of wild-type WNV (data not shown).
C102A substitution is associated with a virulent phenotype in
mice
A C102A substitution was engineered to determine if the
attenuation of C102S was due to disruption of a disulfide bond.
The C102A substitution was associated with a less drastic
temperature sensitive phenotype, i.e., a reduction in efficiency
of plaquing of only 1.9 log10 pfu/ml at 41 °C versus 37 °C
(Table 1). Sequencing of plaque picks taken at 41 °C shows that
the C102A substitution was retained in marked contrast to
C102S. In addition, this virus exhibited a neuroinvasive
phenotype similar to wild-type WNV with an i.p. LD50 value
of 0.7 pfu. Brains were harvested from selected animals
succumbing to C102A virus infection, and viral RNA was
isolated. Sequencing of RT-PCR products revealed that the
designed C102A substitution was present indicating that this
substitution retained the neuroinvasive phenotype of the wild-
type WNV.
RNA and protein levels in wild-type and C102S virus-infected
Vero cell culture
To determine where the block in viral replication occurred
with respect to the C102S virus at 41 °C, intracellular viral RNA
and protein levels were assayed in Vero cells at both 37 °C and
41 °C. Quantitative real-time RT-PCR results indicated
comparable levels of viral RNA synthesis for both wild-type
and C102S viruses in Vero cells at 37 °C (Fig. 3A, left panel). In
contrast, there was a sharp reduction in synthesis of viral RNA
levels in C102S virus-infected cells compared to wild-type
virus-infected cells at 41 °C. Unexpectedly, initial intracellular
RNA levels for the C102S virus-infected cells appeared
significantly higher than infectivity viral titers would indicate.
We attribute this to the presence of nonreplicating viral particles
in the inoculum. Viral protein levels were measured by Western
blot utilizing an anti-WNV E protein domain III antiserum to
probe cell lysates generated from virus-infected Vero cells (Fig.
3B). Viral E protein levels for both wild-type and C102S virus-
infected cells were comparable at 37 °C, while viral protein
levels were sharply reduced in C102S virus-infected cells
Fig. 3. Viral RNA (A) and protein (B) levels from cell lysates of wild-type and C102S mutant infected cell cultures incubated at 37 °C and 41 °C. (A) TaqMan
quantitative real-time RTPCR was conducted on total cellular RNA preparations using primers localizing to the WNV 3′-UTR. Data were converted to RNA genome
equivalents (GEQ) utilizing a standardized curve. (B) Protein levels were assayed from crude cellular lysates, and Western blots were probed with rabbit anti-Domain
III polyclonal antibody. β-Actin levels were used as an internal standard.
250 Rapid Communicationcompared to wild-type virus-infected cells at 41 °C. β-Actin
was used as an internal standard, and these protein levels were
similar in all samples.
Discussion
In this study, we have investigated the role of cysteine
residues in the function of the flavivirus NS4B protein using
WNV as a model. Although there are four cysteine residues
(102, 120, 227, and 237), only the cysteine-to-serine mutation at
residue 102 altered the phenotypic properties of the virus.
Specifically, mutation of residue 102 attenuated mouse
virulence and induced a temperature sensitive phenotype. As
described in the introduction, there is evidence to suggest that
the central region of NS4B plays a role in the virulence
phenotype of flaviviruses. However, this is the first time a single
engineered amino acid substitution in this region has been
shown to directly confer an attenuated phenotype in an animal
model. Examination of a hydrophobicity plot (Fig. 1B) of NS4B
utilizing predictions generated by the SOSUI program (Hir-
okawa et al., 2003) suggests that NS4B C120 resides in a
transmembrane region, C227 and C237 are in the C-terminus,
and C102 may reside near the junction of an ectodomain and
two transmembrane regions. Interestingly, this cysteine residue
is conserved in all members of the JE and DEN genetic groups(Fig. 1A), suggesting that the C102S mutation at this locus may
attenuate all of these viruses.
The C102S mutant was found to be attenuated by at least
10,000-fold for mouse neuroinvasiveness and at least 5000-fold
for mouse neurovirulence, compared to the wild-type WNV.
Such high levels of attenuation for mice have been reported
associated with chimeric constructs such as the WNV prM-E/
DEN4 chimera (Pletnev et al., 2002) and WNV prM-E/YFV 17-
D chimera (Monath et al., 2001), which express the prM-E
structural genes ofWNVin the attenuated genetic background of
the heterologous DEN4 virus and YFV, respectively. The fact
that a single nucleotide change in WNV can lead to such a
dramatic attenuated phenotype implies that the NS4B protein
encodes a critical function in virulence that may not always be
readily identifiable in cell culture. The C102S mutant multiplied
comparably to wild-type WNV in Vero, Neuro2A, and C6/36
cells at permissive temperatures. However, the C102S mutant
displayed a reduced replication phenotype in Vero cells at 41 °C,
though not at 39.5 °C, relative to wild-type WNVand the other
three mutants studied. Analysis of intracellular viral RNA and
protein levels correlated closely with viral infectivity titers for
wild-type WNV. In contrast, the C102S virus exhibited higher
than expected initial RNA levels relative to observed titers. Low
levels of viral RNA were synthesized in C102S virus-infected
cells at 41 °C between 0 and 24 h; however, viral RNA levels at
251Rapid Communicationthis temperature decreased between 24 and 48 h. This is
presumably due to a degradation of the input viral RNA.Western
blots showed comparable levels of viral E protein for both wild-
type and C102S virus-infected cells at 37 °C, while an E protein
band was not visualized at 41 °C in the C102S virus-infected
cells. In addition, a∼33-kDa bandwas visualized with theWNV
anti-E domain III antiserum at 41 °C beginning at 12 h for both
wild-type and C102S infected cells, while this band was not
visible in the 37 °C blots. However, this band was also seen in
mock-infected cells grown at 41 °C, indicating that presence of
virus was not required for induction of this product (data not
shown). In combination, these data suggest that reduced viral
RNA synthesis is at least partially responsible for the observed
temperature sensitive phenotype. Alternatively, the disparity
between observed RNA levels and lack of detectable viral titers
with the C102S mutant at early time points could suggest
blockage of viral assembly or budding.
Examination of the viremias from C102S-infected mice
demonstrated that the virus multiplied, but at lower levels than
observed for the wild-type virus. Viremias associated with the
attenuated C102S NS4B mutant are different than those
observed for the previously described attenuated NY99/E154
mutant (Beasley et al., 2005). The NY99/E154 virus contains a
mutation that disrupted the glycosylation site in the envelope
protein and exhibited significant attenuation of the mouse
neuroinvasive phenotype. This virus never reached detectable
levels in the serum (a level of detection of 1.4 log10 pfu/ml) but
exhibited an i.p. LD50 value of 126 pfu. In contrast, the NS4B
C102S virus reached a peak serum titer of 3.4 log10 pfu/ml but
still had an LD50 value of greater than 10,000 pfu. These data
indicate that the mechanism of attenuation associated with the
NS4B C102S mutation is distinct from that associated with
disruption of envelope protein glycosylation. A C102A
substitution was associated with a less drastic temperature
sensitive phenotype at 41 °C when compared to C102S and a
neuroinvasive phenotype comparable to wild-type WNV. This
demonstrated that a cysteine-specific mechanism such as
disulfide-bonding or palmitoylation was not responsible for
the mouse attenuation phenotype.
Future studies will focus on elucidating the molecular
mechanism of attenuation conferred by the C102S substitution.
Recent reports by other authors indicate that the flaviviral NS4B
protein is capable of altering host cellular signaling pathways.
Tong et al. (2002) described an interaction between HCV NS4B
and Hsp70 utilizing a yeast 2-hybrid screen, and Munoz-Jordan
et al. (2004) described inhibition of Stat-1 phosphorylation in
response to DEN2 infection or overexpression of DEN2 NS4B
implying that altering the IFN-signaling response is one of the
functions of NS4B. Munoz-Jordan et al. (2005) constructed
deletion mutants of the NS4B protein and determined that amino
acids 77–125 of DEN2 NS4B were critical for inhibition of IFN
signaling. The C102 residue is located within this region and
hence may play a role in these pathways. The interactions
between virus and host are undoubtedly complex, but the
identification of an attenuated phenotype associated with the
C102S mutation provides a platform to further study the role of
the NS4B protein. In addition, engineering attenuating muta-tions into the NS4B protein may prove to be a useful strategy in
designing new flaviviral vaccines given that reversion was not
seen in vivo.
Methods and materials
Site-directed mutagenesis
The 3′ plasmid of the WNV infectious clone WN/IC P991
served as the template for introduction of mutations (Beasley et
al., 2005). Mutagenesis was conducted using the QuickChange
XL Site-Directed Mutagenesis Kit (Stratagene) following the
protocol accompanying the kit. Sets of primers were designed
for each engineered mutation (C102S, C120S, C227S, C237S,
C102A) including sufficiently long flanking regions to obtain a
predicted melting temperature of at least 78 °C. Primer
sequences are available upon request. Mutagenesis reactions
were carried out in a thermocycler following specific cycling
parameters listed in the protocol. Products were then digested
with Dpn I to remove parental DNA and transformed into XL-
10 Gold ultracompetent cells that were plated on LB/ampicillin
plates. Four colonies from each mutagenesis reaction were
picked and miniprepped, and sequencing was conducted to
confirm the presence of the desired mutation and absence of
additional mutations in the NS4B gene. Appropriate plasmids
were grown in 200-ml cultures to obtain concentrated DNA for
further manipulation.
Construction and transfection of recombinant viruses
The WNV NY-99 infectious clone was constructed in two
plasmids as described by Beasley et al. (2005). 3 μg each of 5′
pWN-AB and 3′ pWN-CG infectious clone plasmids were
digested simultaneously with NgoMIV and XbaI restriction
enzymes. Appropriate DNA fragments were visualized on an
agarose gel and purified using a gel extraction kit (Qiagen).
Fragments were ligated overnight at room temperature using T4
DNA ligase. DNAwas linearized by digesting with XbaI, treated
with Proteinase K, and was extracted twice with phenol/
chloroform/isoamyl alcohol and once with chloroform. DNA
was ethanol precipitated, and the pellet was resuspended in TE
buffer. The resulting product served as the template for
transcription using a T7 ampliscribe kit (Epicentre) and A-cap
analog (NEB). Following a 3-h incubation at 37 °C, the
transcription reaction was added to 1.5 × 107 Vero cells
suspended in 500uL PBS, and transfection was accomplished by
using electroporation. The cells were placed in a cuvette (0.2-cm
electrode gap) on ice, pulsed twice at 1.5 kV, infinite Ohms, and
25 uF, incubated at room temperature for 10 min, transferred to
75-cm2 flasks containing MEM with 8% FBS, and incubated at
37 °C and 5% CO2. Viruses were harvested at day 5 or 6 post-
transfection, when CPE was evident. Culture medium contain-
ing virus was clarified by centrifugation for 5 min at 1200 rpm,
and 1-ml aliquots were stored at −80 °C. Viral RNA was
extracted using the Viral RNA Mini-Spin kit (Qiagen). The
presence of the engineered NS4B mutation was confirmed by
amplifying the NS4B region using the Titan One-Step RT-PCR
252 Rapid Communicationkit (Roche) and DNA sequencing. Full-length genomic
sequencing was conducted on the C102S mutant virus to
check for the presence of additional mutations. None were
identified.
Plaque assays
Titers of recombinant viruses were determined by plaque
titration in Vero cells at both 37 °C and 41 °C. Vero cells were
allowed to grow to approximately 90% confluency in 6-well
plates. Growth medium (MEM with Earle's salts and L-
glutamine (Gibco) supplemented with 8% bovine growth
serum (BGS) (Hyclone), 100 units/ml penicillin (Gibco), and
100 μg/ml streptomycin (Gibco)) was removed, and cells were
rinsed with PBS. Serial dilutions of each virus were adsorbed,
200 μl per well, for 30 min before overlaying the cell monolayer
with a 50:50 mixture of 2% agar (Sigma) and 2× MEM (Gibco)
containing 4% BGS. Two days following the first agar overlay,
2 ml of a mixture of 2% agar and 4% BGS 2× MEM containing
2% neutral red was added to each well. Plaques were visualized
and counted the following day, and viral titers were calculated.
Virus found to be temperature sensitive at 41 °C was plaqued at
39.5 °C to better define the temperature-sensitive phenotype.
Mouse virulence studies
Recombinant viruses were diluted in PBS to obtain doses
ranging from 103 pfu to 10−1 pfu. Each virus dose was injected
in a volume of 100 μl intraperitoneally into groups of five 3- to
4-week-old female NIH Swiss mice. Clinical signs of infection
were noted during the following 14 days, and the LD50 value
was calculated for each virus. Three weeks following
inoculation, surviving mice were challenged intraperitoneally
with a uniformly lethal dose (100 pfu) of wild-type NY-99
WNV to determine if they had developed a protective immune
response. If a virus was found to be attenuated via the IP route, it
was administered by the intracerebral (IC) route to investigate
the mouse neurovirulence phenotype.
Growth curves
Growth curves were conducted for wild-type WNV virus and
the four cysteinemutants in Vero cells at both 37 °C and 41 °C, in
Neuro2A cells at 37 °C, and in C6/36 cells at 28 °C. Cells were
grown in 6-well plates in appropriate media and were infected
with 200 μl virus diluted in PBS at a MOI of 0.01. After
adsorbing virus for 30 min, the cells were washed three times
with PBS, and 4 ml of the appropriate medium was added. At 0,
12, 24, 48, 72, and 96 h after infection, 0.5-ml samples were
removed and frozen at −80 °C. The harvested samples were then
plaque titrated in 12-well plates of Vero cells. Each growth curve
was performed in triplicate, and each plaque assay was
undertaken in duplicate. Vero cells were grown in MEM with
Earle's salts and L-glutamine (Gibco) supplemented with 8%
BGS, 100 units/ml penicillin, and 100 μg/ml streptomycin.
Neuro 2A cells were grown in MEM with Earle's salts and L-
glutamine supplemented with 8% BGS, 100 units/ml penicillin,100 μg/ml streptomycin, 0.075% sodium bicarbonate (Sigma),
and 1 mM sodium pyrubate (Sigma). C6/36 cells were grown in
MEMwith Earle's salts and L-glutamine supplemented with 8%
fetal bovine serum (FBS) (Hyclone), 100 units/ml penicillin,
100 μg/ml streptomycin, and 0.075% tryptose phosphate broth.
RT-PCR and Western blots
Virus-infected Vero cell monolayers (MOI of 0.01) were
rinsed three times with PBS, and total viral and cellular RNA
was isolated from cellular lysates at 0, 12, 24, and 48 h after
infection by using the Qiagen RNeasy Mini kit. A ∼100-bp
fragment of the 3′ noncoding region was amplified using
TaqMan one-step RT-PCR as described by Vanlandingham et al.
(2004). Utilized primers were first described by Lanciotti et al.
(2000). RNA levels were quantified by comparison to a
standard curve generated from serial 10-fold dilutions of
WNV RNA. To determine protein levels, cell lysates were
generated by solubilizing virus- or mock-infected Vero mono-
layers in 0.5 ml of RIPA buffer containing 10% SDS. Equal
volumes (8 μl) of each lysate were run in 12.5% SDS-PAGE
gels and transferred to PVDF membranes in duplicate. One
membrane was probed with rabbit polyclonal anti-WNV
envelope domain III antibody to determine viral E protein
levels, while the other membrane was probed with mouse anti-
β-actin antibody (Sigma) to assay cellular protein levels.
Viremia curves
NIH Swiss mice were inoculated with 100 pfu of either wild-
type WNV or C102S virus via the intraperitoneal route. Three
mice were sacrificed for each virus every day for 6 days. Brains
were harvested, and blood was drawn by cardiac puncture.
Brains were homogenized, and homogenates were subjected to
plaque assays to determine viral titers in the brain. The limit of
detection was 2.7 log10 pfu/brain. Viral RNA was also isolated
from brains (Qiagen) and was subjected to RT-PCR utilizing the
Titan kit (Roche) to detect low levels of virus in the brain below
the level of detection for plaque assays. Blood from cardiac
puncture was spun down, and serum was removed and frozen.
Serum samples were plaqued to determine viral titers, and the
limit of detection was 1.7 log10 pfu/ml.
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